韩国低死亡率背景下轮状病毒疫苗国家免疫规划的成本效果分析
该研究采用年龄结构静态队列模型,模拟2018至2027年韩国十个年度出生队列,评估将RV1和RV5纳入国家免疫规划相比不接种的成本效果。结果显示,RV1和RV5的增量成本效果比分别为每避免一个DALY 12,432美元和30,081美元,加权平均为21,698美元,低于韩国常用支付意愿阈值人均GDP 30,000美元,提示纳入国家免疫规划具有成本效果。
要点
- RV1和RV5纳入NIP相比不接种可分别避免4799和5068个DALY。
- RV1和RV5的ICER分别为每DALY 12,432美元和30,081美元。
- 加权平均ICER为21,698美元/DALY,低于人均GDP阈值30,000美元。
核心结论
- 在韩国低轮状病毒胃肠炎相关死亡率背景下,将轮状病毒疫苗纳入国家免疫规划相比不接种具有成本效果。
研究设计与样本
- 采用透明的年龄结构静态队列模型,模拟2018至2027年韩国十个年度出生队列的儿童经历。
主要发现
- 纳入RV1和RV5的增量成本分别为59,662,738美元和152,444,379美元。
- RV1和RV5可分别避免4799和5068个DALY。
- 从社会视角,RV1和RV5的ICER分别为每DALY 12,432美元和30,081美元。
- 按当前自愿接种市场份额加权,两种疫苗的加权平均ICER为21,698美元/DALY。
关键数值与推荐
- 估算的ICER低于韩国卫生技术评估常用的支付意愿阈值1倍人均GDP(30,000美元)。
临床怎么用
- 可为韩国将轮状病毒疫苗纳入国家免疫规划提供成本效果证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea. Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq®; RV5) and attenuated human strain originated monovalent vaccine (Rotarix®; RV1), have been available for voluntary vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included in the National Immunization Program (NIP), partly because of the low associated mortality rate. We assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP implementation in South Korea. Using a transparent age-structured static cohort model, we simulated the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVs in the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RV1 and RV5, respectively. The introduction of RV1 and RV5 can prevent 4799 disability-adjusted life years (DALYs) and 5068 DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV into the NIP versus no vaccination were 12,432 USD per DALY averted for RV1 and 30,081 USD per DALY averted for RV 5. The weighted average for the ICERs of the two vaccines computed using the market share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The estimated ICER was below 1 × gross domestic product per capita (30,000 USD), which has been a commonly used willingness-to-pay threshold for health care technology assessment in South Korea, suggesting that introducing RVs into the NIP would be cost-effective.
引用
- Lee H, Park SY, Clark A, et al. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. Vaccine. 2019. PMID: 31326252. doi:10.1016/j.vaccine.2019.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。